This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

OvaScience Appoints Hugh Taylor, M.D., To Scientific Advisory Board

OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for female infertility, announced today the appointment of Hugh Taylor, M.D., the Anita O'Keeffe Young Professor of Obstetrics, Gynecology, and Reproductive Sciences and Professor of Molecular, Cellular, and Developmental Biology at the Yale School of Medicine and Chief of Obstetrics and Gynecology, Yale-New Haven Hospital, to its Scientific Advisory Board. OvaScience also established a research collaboration with Dr. Taylor to develop potential new treatments and diagnostic markers for endometriosis, a leading cause of female infertility. 1

“Dr. Taylor is a world expert and pioneer in the field of endometriosis, a disease that is frequently misdiagnosed and lacking in new treatment options for patients,” said Arthur Tzianabos, Ph.D., Chief Scientific Officer of OvaScience. “We look forward to working with Dr. Taylor to develop new methods for treating and diagnosing this leading cause of female infertility.”

Dr. Taylor has more than 25 years of experience as a clinician and researcher in reproductive medicine. His research focuses on stem cells, uterine development and endometriosis, work that has led to the publication of more than 125 articles. He is currently Editor-in-Chief of Reproductive Sciences. In 2013, Dr. Taylor was recognized by the IVI Foundation for producing the best research in reproductive medicine and in 2012, he was named Honoree of the Year by the Endometriosis Foundation. Dr. Taylor received his undergraduate training at Yale University and received his medical degree from the University of Connecticut School of Medicine. He completed his residency in Obstetrics and Gynecology at Yale. His postdoctoral training included a fellowship in Reproductive Endocrinology and Infertility as well as a fellowship in Molecular Biology, both at Yale.

“This work will help us continue to explore how endometrial stem cells and certain biomarkers of disease can be used to develop new treatments and potentially non-invasive diagnostics for endometriosis,” said Hugh Taylor, M.D., Professor of Obstetrics, Gynecology, and Reproductive Sciences and Professor of Molecular, Cellular, and Developmental Biology at the Yale School of Medicine and Chief of Obstetrics and Gynecology, Yale-New Haven Hospital. “Our research and OvaScience’s advances in its egg precursor cell technology platform offer exciting possibilities for helping patients who are experiencing the painful effects of endometriosis and infertility.”

Stock quotes in this article: OVAS 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs